Sorrento Therapeutics market cap is $368.9 m, and annual revenue was $21.19 m in FY 2018

Sorrento Therapeutics Gross profit (Q1, 2019)3.8 M

Sorrento Therapeutics Gross profit margin (Q1, 2019), %62.4%

Sorrento Therapeutics Net income (Q1, 2019)-146.5 M

Sorrento Therapeutics EBIT (Q1, 2019)-123.2 M

Sorrento Therapeutics Cash, 31-Mar-201991 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 460.1k | 3.8m | 4.6m | 8.2m | 151.9m | 21.2m |

| 731% | 20% | 78% | |||

## Cost of goods sold | 2.0m | 811.0k | 3.9m | 7.1m | ||

## Gross profit | 2.6m | 7.3m | 147.9m | 14.1m | ||

| 58% | 90% | 97% | 67% | ||

## R&D expense | 9.0m | 24.0m | 31.3m | 42.2m | 55.5m | 77.0m |

## General and administrative expense | 6.3m | 10.0m | 20.1m | 24.2m | 38.3m | 63.6m |

## Operating expense total | 22.1m | 34.0m | 78.6m | 104.9m | 126.5m | 171.6m |

## EBIT | (21.7m) | (34.7m) | (74.0m) | (96.8m) | 25.3m | (150.4m) |

| (4709%) | (908%) | (1612%) | (1187%) | 17% | (710%) |

## Interest expense | 253.2k | 1.6m | 1.7m | 1.6m | 5.0m | 57.6m |

## Interest income | 9.6k | 12.0k | 24.0k | 272.0k | 241.0k | 921.0k |

## Pre tax profit | (13.8m) | (64.8m) | 15.3m | |||

## Income tax expense | (1.7m) | 36.3m | (896.0k) | (36.0m) | (6.3m) | |

## Net Income | (21.9m) | (34.7m) | (50.1m) | (63.9m) | 11.1m | (212.5m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 31.7m | 71.9m | 39.0m | 82.4m | 20.4m | 158.7m |

## Current Assets | 32.6m | 73.9m | 141.0m | 89.7m | 29.7m | 179.6m |

## PP&E | 2.4m | 2.3m | 7.2m | 12.7m | 19.3m | 24.4m |

## Goodwill | 24.0m | 24.0m | 20.6m | 41.5m | 38.3m | 38.3m |

## Total Assets | 92.6m | 141.5m | 343.5m | 401.6m | 431.6m | 624.1m |

## Accounts Payable | 2.2m | 1.7m | 1.3m | 8.3m | 9.9m | 13.8m |

## Current Liabilities | 5.5m | 9.6m | 30.9m | 76.1m | 79.0m | 61.6m |

## Long-term debt | 4.4m | 8.8m | 4.4m | 47.1m | ||

## Total Debt | 47.1m | |||||

## Total Liabilities | 315.1m | 225.0m | 416.6m | |||

## Additional Paid-in Capital | 99.7m | 176.2m | 184.9m | 303.9m | 413.9m | 626.7m |

## Retained Earnings | (67.5m) | (113.3m) | (174.3m) | (165.1m) | (367.7m) | |

## Total Equity | 66.8m | 108.7m | 140.9m | 86.5m | 206.6m | 207.5m |

## Debt to Equity Ratio | 0.5 x | |||||

## Debt to Assets Ratio | 0.1 x | |||||

## Financial Leverage | 1.4 x | 1.3 x | 2.4 x | 4.6 x | 2.1 x | 3 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (21.9m) | (34.7m) | (50.1m) | (63.9m) | 11.1m | (212.5m) |

## Depreciation and Amortization | 1.3m | 3.2m | 2.4m | 2.9m | 7.1m | 9.1m |

## Accounts Receivable | (2.2m) | |||||

## Inventories | (3.2m) | |||||

## Accounts Payable | 878.6k | (497.0k) | (2.7m) | 3.7m | 1.6m | 3.6m |

## Cash From Operating Activities | (16.5m) | (28.8m) | (42.1m) | (70.9m) | (99.2m) | (111.8m) |

## Purchases of PP&E | (420.2k) | (591.0k) | (3.7m) | (6.9m) | (11.0m) | (11.2m) |

## Cash From Investing Activities | (503.5k) | (10.6m) | 12.6m | (17.5m) | (16.5m) | (21.2m) |

## Cash From Financing Activities | 43.6m | 79.6m | (3.3m) | 131.7m | 53.7m | 326.0m |

## Interest Paid | 1.5m | 1.6m | 1.3m | 3.5m | 1.6m | |

## Income Taxes Paid | 800.0 | 6.0k | 3.0m | 2.0k | 34.0k | 6.0k |

USD | Y, 2019 |
---|---|

## Financial Leverage | 5.2 x |